1.	A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: Tg 511-08-01, NCT01156584
2.	Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: APS001F-001, NCT01562626
3.	Study of a Retroviral Replicating Vector to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor Phase: Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: Tg 511-11-01, NCT01470794
4.	A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas Phase: No phase specified Type: Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08002, NCI-2010-01388, NCT01172964